ReviewTheranostics2022
Theranostic nanoparticles for the management of thrombosis.
Review in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Deep learning-guided high-throughput screening and molecular dynamics simulations facilitate the discovery of potential FXIIa inhibitors.Journal of molecular modeling · 2026Article
- Ultrasound-Mediated Thrombolysis: From Mechanistic Insights to Advanced Nanoplatforms and Clinical Translation.Advanced healthcare materials · 2026Review
- Polymeric anti-platelet carriers for the precision-targeting of age-related cardiovascular and cerebrovascular diseases.Materials today. Bio · 2026Review
- Targeted Thrombolysis via CCR2-Engineered Macrophage-Mimicking Microbubbles Safely Ablates Venous, Arterial, and Microvascular Thrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature.International journal of nanomedicine · 2026Review
- Costunolide Reduces DN Inflammatory Response and Renal Thrombosis by Inhibiting NET Formation.Journal of diabetes research · 2025Article
- Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems.Molecules (Basel, Switzerland) · 2024Review
- Progress of nanomaterials in the treatment of thrombus.Drug delivery and translational research · 2024Review
- RGD peptide modified RBC membrane functionalized biomimetic nanoparticles for thrombolytic therapy.Journal of materials science. Materials in medicine · 2023Article
- Biogenic Selenium Nanoparticles in Biomedical Sciences: Properties, Current Trends, Novel Opportunities and Emerging Challenges in Theranostic Nanomedicine.Nanomaterials (Basel, Switzerland) · 2023Review
- Biomaterials-Enabled Antithrombotics: Recent Advances and Emerging Strategies.Molecular pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute thrombosis and thromboembolisms are one of the leading causes of mortality and morbidity in both developed and developing countries, placing a huge burden on health and economic systems. Early diagnosis is critical but currently limited in accuracy and hampered by a narrow time frame, where the short therapeutic window also severely restricts treatment options. Additionally, clinically used antithrombotics and thrombolytics suffer from severe side effects and are limited in efficacy by a short half-life and susceptibility to degradation. The use of systems containing both diagnostic and therapeutic moieties, known as theranostics, can potentially improve patient outcomes by increasing the precision and efficacy of diagnosis and treatment, enabling personalised and precision medicine. Leveraging nanomedicine may further improve treatment by improving the system's pharmacokinetic properties including controlled drug delivery. This review provides an overview of the development of such theranostic nanoparticle systems, with a focus on approaches that may be utilised to usher this field towards clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.